<DOC>
	<DOCNO>NCT00319267</DOCNO>
	<brief_summary>The aim study demonstrate exposure bosentan child idiopathic pulmonary arterial hypertension ( PAH ) familial pulmonary arterial hypertension , use pediatric formulation , similar adult PAH evaluate tolerability safety pediatric formulation bosentan patient population .</brief_summary>
	<brief_title>Bosentan Children With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Signed informed consent parent legal representative . Males females &gt; = 2 &lt; 12 year age . Idiopathic PAH familial PAH diagnose right heart catheterization ( Clinical classification pulmonary hypertension , Venice 2003 ) . World Health Organization ( WHO ) functional class II III . Oxygen saturation ( SpO2 ) &gt; = 88 % ( rest , room air ) . PAH treatmentna√Øve patient patient already treat either : Bosentan monotherapy Intravenous epoprostenol monotherapy Intravenous inhale iloprost monotherapy Combination bosentan intravenous epoprostenol Combination bosentan intravenous inhale iloprost . All patient start study drug ( bosentan pediatric formulation ) 2 mg/kg twice daily ( b.i.d . ) , whether previously treat bosentan . PAH therapy stable least 3 month prior Screening . Stable treatment calcium channel blocker , , least 3 month prior Screening . Patient 's PAH condition stable least 3 month prior Screening . PAH associate condition idiopathic familial PAH . Nonstable patient , e.g. , history ( last 3 month prior Screening ) recurrent syncope , sign symptom noncompensated right heart failure . Need plan wean patient intravenous epoprostenol , intravenous , inhaled iloprost . Body weight &lt; 4 kg . Systolic blood pressure &lt; 80 % , low limit normal range , accord age gender . AST and/or ALT value &gt; 3 time upper limit normal range . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C. Hemoglobin and/or hematocrit level &lt; 75 % low limit normal range . Pregnancy . Known intolerance hypersensitivity bosentan excipients .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>bosentan</keyword>
	<keyword>child</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
</DOC>